Drug Profile

LAE 120

Alternative Names: LAE-120

Latest Information Update: 15 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Laekna Therapeutics
Class Antineoplastics
Mechanism of Action USP1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

07 Apr 2024 Pharmacodynamic data from a preclinical study in breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
07 Apr 2024 Pharmacodynamics data from preclinical trial in Cancer released by Laekna Therapeutics
16 Jun 2023 Laekna Therapeutics announces intention to submit IND to US FDA or NMPA for Cancer in Q4 of 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com